Larimar Therapeutics, Inc. 8-K

What Happened

• Larimar Therapeutics, Inc. announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025 in a press release issued March 19, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The Form 8-K was signed by President and CEO Carole S. Ben‑Maimon, M.D.

Key Details

• Event: Item 2.02 filing announcing Q4 2025 and full‑year 2025 results (press release furnished).
• Date filed: March 19, 2026.
• Period covered: Fourth quarter 2025 and year ended December 31, 2025.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8‑K; the report was signed by CEO Carole S. Ben‑Maimon, M.D.

Why It Matters

• This 8‑K provides Larimar’s most recent quarterly and annual performance snapshot; investors should read the furnished press release (Exhibit 99.1) for revenue, earnings, cash position, and any operational or program updates that could affect valuation.
• Because the filing is an Item 2.02 disclosure (results of operations), it is a timely source of earnings and operational information that may influence short‑term trading and longer‑term investment decisions.